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OZ78 and MT04 are promising drug candidates against fascioliasis (fasciolosis). We determined basic
pharmacokinetic (PK) parameters of OZ78 and MT04 in uninfected rats. Rats were treated with single oral
doses of 50 mg/kg OZ78 or MT04. Blood samples were withdrawn at selected time points post treatment
and the plasma concentrations were quantiﬁed by a validated liquid chromatography/mass spectrometry
(LC/MS) method. The LC/MS method for MT04 and OZ78, initially developed for sheep plasma analysis,
was adapted for rat plasma. In vitro pharmacodynamic studies with Fasciola hepatica incubated in solu-
tions of either test agent complemented our work. The adapted and validated method was precise and
accurate to measure OZ78 and MT04 in rat plasma. Accuracies for MT04 ranged from 87.9% to 104.7%
with precisions not exceeding 14.3%. Precisions for OZ78 were lower than 9.8% and accuracies were
between 88.4% and 105.3%. Following oral administration, maximum plasma concentrations (Cmax) of
MT04 and OZ78 were 49.8 and 70.1 lg/ml after 2.7 h and 1.6 h, respectively (p > 0.05). The estimated area
under the plasma time curves (AUCs) were comparable for MT04 and OZ78. Mean elimination half-lives
(t1/2) of MT04 and OZ78 covered a range from 1 to 7 h. In vitro studies demonstrated that the fasciocidal
activity of MT04 and OZ78 was dependent on the incubation-time, with exposure of ﬂukes for 24 h to the
drugs not being sufﬁcient to kill the worms. In conclusion, differences in PK parameters of MT04 and
OZ78 were observed in rats. However, further studies (e.g. in infected rats) are necessary to characterize
these drugs in greater detail.
 2012 Australian Society for Parasitology Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Fascioliasis (fasciolosis) caused by the food-borne trematodes
Fasciola hepatica and Fasciola gigantica is a major public health
problem and of signiﬁcant veterinary importance (Mas-Coma
et al., 2005; Robinson and Dalton, 2009). Recently the global bur-
den of fascioliasis was calculated for the ﬁrst time. It has been esti-
mated that 2.6 million people are infected with Fasciola spp. and
299,510 people suffer from heavy fascioliasis resulting in
35,206 years lived with disability (Fürst et al., 2012). The benz-
imidazole triclabendazole is the ﬁrst choice treatment against
fascioliasis in human and veterinary medicine because of its excel-
lent activity against both, adult and juvenile worms (Keiser et al.,
2005; Fairweather, 2011). However, the development of triclaben-
dazole resistance can not be ignored and therefore new treatmentsPublished by Elsevier Ltd.
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Open acshould be discovered and developed (Fairweather and Boray, 1999;
Keiser and Utzinger, 2007).
The ozonides OZ78 and MT04 are promising fasciocidal drug
candidates (Vennerstrom et al., 2004; Keiser et al., 2006; Kirchhofer
et al., 2011). Both drugs have shown high in vitro activities against
adult F. hepatica. Flukes incubated in MT04 or OZ78 at concentra-
tions of 50 and 100 lg/ml, respectively were dead after 72 h (Keiser
and Morson, 2008a; Kirchhofer et al., 2011). More importantly, in
rat studies, both compounds were active against juvenile (acute)
and adult (chronic) infections at oral doses of 50–100 mg/kg (Keiser
et al., 2006; Kirchhofer et al., 2011), whereas MT04 showed slightly
superior activity compared to OZ78. The ozonide structures of OZ78
andMT04 are both characterized by an acidic functional group cou-
pled to a peroxidic bridge and a spiroadamantane substructure,
features shown to be essential for ﬂukicidal activity in rats (Zhao
et al., 2010).
Recently, OZ78 was tested in sheep experimentally infected
with F. hepatica using doses of 50 mg/kg applied orally and subcu-
taneously. However, no effect on the worm counts was observed
despite high concentrations measured in plasma after both treat-
ments (Keiser et al., 2010).cess under CC BY-NC-ND license.
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rats might clarify the difference observed in activity between rats
and sheep. The aim of the present study was therefore to deter-
mine the basic pharmacokinetic (PK) parameters of OZ78 and
MT04 in uninfected rats using a recently developed high perfor-
mance liquid chromatography–mass spectrometry (LC/MS) meth-
od for OZ78 and a newly adapted LC/MS method for MT04. Both
drugs were applied orally at 50 mg/kg to uninfected rats. In addi-
tion, in vitro studies with both test agents simulating the observed
in vivo conditions complemented our work.2. Materials and methods
2.1. Animal studies
Animal experiments were carried out in accordance with Swiss
legislation on animal welfare.
Female Wistar rats (weight: 150 g) were purchased from
Charles River (Germany). The animals were housed in standard
cages and maintained under a 12 h light/dark cycle with access
to laboratory chow and water ad libitum. For kinetic studies, rats
had an indwelling cannula implanted in the right jugular vein
(Bittner et al., 2003).
2.2. Drugs and drug formulation
OZ78 and MT04 (Fig. 1) were kindly supplied by the College of
Pharmacy, University of Nebraska Medical Center (Omaha, USA).
Drugs suspensions were prepared in 7% (v/v) Tween 80 and 3%
(v/v) ethanol 96% shortly before administration to rats.
OZ352 (Fig. 1, also provided by the College of Pharmacy, Univer-
sity of Nebraska Medical Center) was used as internal standard (IS)
for analysis.
2.3. Pharmacokinetic study
Pharmacokinetic proﬁles were studied in rats treated orally
with 50 mg/kg OZ78 (n = 4) and MT04 (n = 4). Venous blood sam-
ples (0.2 ml) were collected using lithium-heparin coated tubes
(Sarstedt, Nümbrecht, Germany) at 0, 30, 60, 120, 180, 240, 360,
and 1440 min post-treatment. The blood volume was replaced
with an equal volume of 0.9% saline solution. Samples were
allowed to stand for 20 min at RT and subsequently centrifuged
at 200 rpm for 15 min. Obtained plasma samples were stored at
20 C prior to analysis.
2.4. Liquid chromatography mass spectrometry analysis
OZ78 and MT04 were analyzed as described previously
(Kirchhofer et al., 2010). In brief, analytes were separated by a high
performance liquid chromatography (HPLC) system (Shimadzu,Fig. 1. Chemical structures and molecular weightsKyoto, Japan) connected to an API 365 triple–quadrupole mass
spectrometer (PE Biosystems, Foster City, CA, USA) with a turbo
ion spray interface. A phenomenex C8 (2) column
(50 mm  2.0 mm, 5 lm; Phenomenex, Brechbühler AG, Schlieren,
Switzerland) was used to separate the respective analyte and the
internal standard (OZ352).
Acetonitrile combined with 5 mM ammonium formate in water
served as mobile phase. A gradient over 14 min was applied at a
ﬂow rate of 0.3 ml/min. OZ78 was detected in negative mode at
m/z ratio of 321.4 and the internal standard was detected at m/z
of 335.4. MT04 was monitored at m/z 337.4 (negative mode,
deprotonated parent compound, M).
Calibration curves of the analyte were prepared by diluting ana-
lyte working solutions with blank sheep plasma. Each calibration
curve consisted of seven calibrators (10, 5, 2.5, 1.25, 0.625,
0.3125, and 0.15625 lg/ml), one zero sample (plasma sample
spiked with 2 lg/ml IS) and one blank plasma sample (plasma
sample processed without IS). The calibration curves were ex-
panded in this study to cover a broader concentration range
(10,000–156.25 ng/ml).
Sample preparation was done by protein precipitation. 900 ll
methanol was added to 300 ll plasma followed by vortex-mixing
for 1 min and centrifugation for 30 min at 16,100g and 4 C. The
supernatant was dried under nitrogen gas and then reconstituted
in a mixture of 50 ll methanol and 150 ll acetonitrile/water (3/
7, (v/v)). The reconstituted sample was transferred into an auto-
sampler vial and stored at 6 C in the CTC HTS PAL autosampler
(CTC Analytics, Zwingen, Switzerland) prior to analysis. A 20 ll ali-
quot of each sample was injected into the LC–MS/MS system.2.5. Validation of the analytical method
The analytical methods were developed initially to analyze
sheep plasma samples and were validated accordingly. For mea-
surements of rat plasma samples, the LC/MS methods were modi-
ﬁed and validated as follows: Rat plasma spiked with OZ78 or
MT04 was mixed with sheep plasma (9/1 or 4/1, (v/v)) followed
by addition of the internal standard solution. Accuracies were cal-
culated as the ratio of the measured concentration to the nominal
concentration. Precisions were calculated using the relative stan-
dard deviations (RSD%). Calibration samples were freshly prepared
and included in each analytical run. For accuracy and precision, a
deviation of <15% was considered acceptable as recommended by
US guidelines of the Food and Drug Administration (FDA, 2001).
It should be noted, that this method can not be used to analyze
rat bile samples due to severe interference with bile salts.2.6. In vitro assay with adult F. hepatica
In vitro studies with F. hepaticawere carried out as described by
Kirchhofer et al. (2011). Adult ﬂukes were recovered from bile(MW) of (A) OZ78, (B) OZ352, and (C) MT04.
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were washed with 0.9% (w/v) NaCl and placed in petri dishes. The
ﬂukes were rinsed with pre-warmed RPMI 1640 culture medium
(Gibco, NY, USA) and pre-incubated for several hours in this med-
ium at 37 C in an atmosphere of 5% CO2. A single adult Fasciola
was placed per well (6-well plate, Costar, MA, USA) containing
5.4 ml RPMI 1640, supplemented with 1% (v/v) antibiotics
(50 lg/ml streptomycin and 50 U/ml penicillin; Sigma, Buchs,
Switzerland), 1% (v/v) drug-solution, and 8% (v/v) of a haemin solu-
tion (Keiser and Morson, 2008a). Adult F. hepatica were incubated
in the presence of 50 lg/ml MT04 or OZ78 for 96 h. In a second ser-
ies of experiments worms were exposed to the drugs for 24 h and
then placed in fresh, drug-free medium for another 72 h. Cultures
were kept at 37 C in an atmosphere of 5% CO2.
The viabilities of treated and untreated Fasciolawere monitored
at 0, 24, 48, 72, and 96 h and compared to control worms. Worms
were examined using a dissecting microscope. Viability was de-
ﬁned on a scale from 4 (normal activity; movements clearly visi-
ble) to 1 (worm dead, no movement observed for two minutes).
Results were expressed as means ± standard error (SE).2.7. Data analysis and statistics
Data analysis was performed with Analyst 1.4.2. software (PE
Biosystems). Microsoft Excel 2003 was used for the statistical anal-
ysis. Student’s t-test was used to compare means of the PK param-
eters, p-values <0.05 were considered to be signiﬁcant. For kinetic
parameter estimation WinNonLin (Version 5.2, Pharsight Corpora-
tion, USA) was used. Maximal plasma concentration (Cmax) and
time to achieve maximal plasma concentration (Tmax) were
observed values. Area under the plasma concentration time curve
(AUC, from 0 to inﬁnity) was calculated by the program using
the linear trapezoidal rule. The elimination half life (t1/2) was
determined by the equation: t1/2 = 0.693/k, where k was estimated
by performing a regression of the natural logarithm of the concen-




























Fig. 2. Plasma concentration versus time proﬁles in rats following 50 mg/kg oral
doses of OZ78 (A) (n = 4) and MT04 (B) (n = 4).3. Results and discussion
Fascioliasis is a disease with a worldwide distribution but nev-
ertheless belongs to the neglected tropical diseases (Hotez et al.,
2006; Fürst et al., 2012). Funding for the identiﬁcation and
development of novel control tools, including drug discovery and
development, has been limited despite disturbing effects of these
diseases on health (Spiegel et al., 2010). This is reﬂected by the fact
that for the treatment of fascioliasis only a single drug, triclaben-
dazole, is available (Keiser et al., 2005). The documented resistance
to triclabendazole and the empty drug pipeline emphasize the
great need to discover and develop novel drugs for the treatment
of fascioliasis (Keiser et al., 2005).
MT04 and OZ78 are promising fasciocidal drug candidates as
documented by studies in vitro and in rats (Kirchhofer et al.,
2011). However, disappointingly OZ78 failed to cure F. hepatica in-
fected sheep (Keiser et al., 2010). We were interested to study PK
parameters of OZ78 in rats to get a deeper insight on the difference
observed between activity of OZ78 in rats and sheep. In addition, it
was our goal to compare the PK parameters of OZ78 and MT04
since activities of these drugs slightly varied in rats. At 50 mg/kg
per os MT04 achieved a complete elimination of worms in rats,
whereas the worm burden reduction of OZ78 was only 52.7% at
this dose (Keiser et al., 2006; Kirchhofer et al., 2011). OZ78 at
100 mg/kg per os cured F. hepatica infected rats (Keiser et al.,
2006).
First, the MT04 method was validated according to the previ-
ously published LC/MS method for OZ78 (Kirchhofer et al., 2010).The same LC/MS method was used as described for OZ78, with
exception that MT04 was detected at m/z 337.4. The calibration
curves of MT04 were linear over a concentration range of
156.25–10,000 ng/ml in sheep plasma with coefﬁcient of correla-
tions (r2) above 0.99. Accuracy and precision were determined
for three batches of QC samples at four concentrations (10, 5,
1.25, and 0.3125 lg/ml). Intra- (n = 3) and inter-batch (n = 9) preci-
sions were below 13.75% and 9.73%, respectively, with accuracies
ranging from 87.2% to 101.7% and 90.5% to 98.9%. These values
were within the suggested range of 15% for accurate and precise
methods as recommended by USFDA (FDA guidance, 2001). Extrac-
tion recoveries of three concentrations (10, 1.25, and 0.3125 lg/
ml) of MT04 in sheep plasma were 74.7 (±16.2)%, 81.6 (±13.5)%,
and 75.4 (±16.7)%, respectively. No interfering signals were ob-
served at the retention time of OZ78 and MT04. Both analytes were
detected at the same retention time. In some samples interfering
peaks near the analyte or IS were visible, however signals did not
inﬂuence peak integration. Selectivity was therefore ensured for
the analytical method.
Dilution of rat plasma samples with sheep plasma is possible as
demonstrated by an additional set of validation experiments.
Mixed plasma quality control samples (10, 5, 1.25, and
0.3125 lg/ml) represented the expected concentration with a devi-
ation of not more than 15%. Precisions for MT04 or OZ78 were be-
low 14.1% and 13.1%, respectively and accuracies ranged from
89.6% to 111.1% for MT04 and OZ78. Validation results from the di-
luted rat plasma samples conﬁrmed that the MT04 and OZ78
methods developed for sheep plasma could be used to measure
rat samples by diluting rat with sheep plasma. The back calculated
concentrations revealed deviations of not more than 15% of the ex-
pected concentrations for MT04 and OZ78. Accuracies for MT04
were between 87.9% and 104.7% with precisions not exceeding
14.3%. Precisions for OZ78 were lower than 9.8% and accuracies
were between 88.4% and 105.3%. The lower limit of quantitation
of the method did not allow to measure samples with concentra-
tions lower than 156.25 ng/ml.
Table 1
Pharmacokinetic parameters of OZ78 and MT04 in uninfected rats after oral administration of 50 mg/kg. For comparison, disposition parameters following treatment of
F. hepatica infected sheep with 50 mg/kg are shown.
Treatment Animal Dose (mg/kg) Cmax (lg/ml) Tmax (h) AUC (lg min/ml) t1/2 (h)
OZ78 oral Rat 50 70.1 (±19.1) 1.6 (±1.6) 29,794.1 (±3,990.6) 2.5 (±1.5)
MT04 oral Rat 50 49.8 (±9.1) 2.7 (±1.2) 31,258.8 (±6,232.7) 6.4 (±5.7)
OZ78 orala Sheep 50 45.8 (±13) 1.0 6,972.0 (±2,820)b 1.0 (±0.1)
Data are presented as mean (±SD).
a Keiser et al. (2010).
b Statistically signiﬁcant to AUC determined in rats p < 0.05.
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picted in Fig. 2(A) and (B) and the corresponding basic PK parame-
ters are summarized in Table 1. A non compartmental model was
used to estimate PK parameters. In our study differences were ob-
served in the drug disposition parameters of MT04 and OZ78.
MT04 reached amean peak concentration of 49.8 ± 9.1 lg/ml (Cmax)
after 2.7 h ± 1.2 (Tmax), whereas for OZ78 a mean peak concentra-
tion of 70.1 ± 19.1 lg/ml (Cmax) was observed after 1.6 h ± 1.6
(Tmax). Twenty-four hours after treatment only traces of the drugs
could be detected in plasma. The estimated half life of MT04 and
OZ78 were 6.4 ± 5.7 and 2.5 ± 1.5 h, respectively. The mean AUC
were 31,258.8 ± 6,232.7 and 29,794.1 ± 3,990.6 lg min/ml for
MT04 and OZ78. However, our ﬁnding should be interpreted with
care since few animals were used, the high inter-individual
variability of PK parameters observed and the few data-pointsmea-
sured in the elimination phase of the drugs. In addition, no statisti-
cal signiﬁcancewas observed between PK parameters calculated for
OZ78 and MT04.
Though, the longer half-life of MT04 might contribute to an in-
creased activity, it is difﬁcult to explain the better activity of MT04
entirely with the obtained PK parameters. It is possible that the
double peroxide bridge feature of MT04 plays an important role
in activity. It is most likely that, similar to the antimalarial activity,
an iron dependent activation of the peroxide core of the artemisi-
nins and synthetic peroxides is the main driver of trematocidal
activity (Keiser and Utzinger, 2007).
A clear difference in PK parameters was observed between rats











Fig. 3. In vitro viability of adult F. hepatica, (A) in the presence of 50 lg/ml MT04 for 9
medium for 72 h) (black squares, dotted line), and (B) in the presence of 50 lg/ml OZ78 fo
medium for 72 h) (black triangles, dotted line) versus control adult F. hepatica (white dA limitation of this face to face comparison is that in the present
work uninfected rats were used, while PK parameters were derived
from sheep, which suffered a chronic Fasciola infection. Keiser et al.
(2009) have recently shown that PK parameters of artesunate and
dihydroartemisinin were dramatically inﬂuenced by the F. hepatica
infection (acute and chronic) in rats (Keiser et al., 2009). However,
strikingly the AUC in rats was 4.3 times higher than in sheep
(29,794.1 ± 3,990.6 versus 6,972.0 ± 2,820 lg min/ml) (p = 0.001).
Note that a dose of 50 mg/kg in sheep corresponds to approxi-
mately 100 mg/kg in rats if normalized to body surface area (Keiser
et al., 2010). A dose of 100 mg/kg OZ78 in rat would presumably
result in a higher AUC and thus the difference in AUC between
sheep and rat would be even more pronounced. Further differences
in PK parameters (e.g. Tmax, Cmax, and t1/2) between sheep and rat
were observed. However, the differences were less pronounced
than the AUC level and were not signiﬁcant (a summary of the
sheep data is given in Table 1). Hence, the therapy failure in sheep
might be explained by the lower total drug exposure of F. hepatica
to OZ78 when compared to rats. Flukes presumably had insufﬁ-
cient duration of exposure to sufﬁcient drug levels and were there-
fore were not killed.
The hypothesis that adequately long plasma levels are required
for fasciocidal activity is supported by ﬁndings obtained in our
pharmacodynamic in vitro studies. To approximately simulate the
measured in vivo conditions, ﬂukes (n = 6 for each concentration)
were incubated in the presence of MT04 or OZ78 at a concentration
of 50 lg/ml for 24 h (followed by incubation in drug free medium)




0 24 48 72 96
B
6 h (black squares), 50 lg/ml MT04 for 24 h (followed by incubation in drug free
r 96 h (black triangles), 50 lg/ml OZ78 for 24 h (followed by incubation in drug free
iamonds). Values are means ± standard error (SE).
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MT04 for 24 h (followed by incubation in drug free medium) were
still alive after 96 h displaying a reduced viability. Worms incu-
bated for 96 h in OZ78 50 lg/ml were alive. However, they re-
vealed a strongly reduced viability. Worms incubated in OZ78 for
24 h (followed by incubation in drug free medium) were affected
to a nearly similar degree as those incubated for 96 h.
Note that adult Fasciola worms are settled in the bile ducts and
gallbladder of the host (Robinson and Dalton, 2009). However, in
the present study drug levels were determined in plasma and not
in bile ﬂuid due to technical limitations of the method. It is most
likely that bile concentrations of OZ78 and MT04 in rats are higher
or have longer half-lives than the determined plasma levels given
the excellent activity of the drugs in rats.
A recently published study in F. hepatica infected sheep with
structurally related compounds, the semi-synthetic artemisinin
(artemether), demonstrated that the treatment outcome was
dependent on the route of administration (Keiser et al., 2008b).
Artemether applied at a single intramuscular (i.m.) dose of
160 mg/kg showed an efﬁcacy of >90%, whereas oral dosages of
40 or 80 mg/kg had no effect on egg and worm counts (Keiser
et al., 2008b). PK parameters were determined from these treat-
ments (Duthaler et al., 2011). It was shown that the AUC after
i.m. application was signiﬁcantly higher than after oral application.
It might be therefore worthwhile to test the activity of intramuscu-
lar applications of OZ78 and MT04 in sheep.
In conclusion, the established LC/MS method for determination
of MT04 is accurate and precise. The MT04 as well as the OZ78 LC/
MS methods could be adapted to measure both sheep and rat plas-
ma samples. We analyzed drug disposition parameters for OZ78
and MT04 in uninfected rats, which pointed to differences between
the drugs. In addition, comparing PK parameters of OZ78 in rats
and sheep revealed a signiﬁcantly lower AUC in sheep and might
therefore provide an explanation for the lack of activity in this spe-
cies. Further studies in F. hepatica infected rats are needed to
strengthen these ﬁndings. Finally, the analytical methods should
be modiﬁed in order to be able to determine bile concentrations
of OZ78 and MT04.Acknowledgments
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